Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly EBITDA Margin of 14257.07% for Q3 2021, down 1149635.0% year-over-year from N/an in Q3 2020, and down 16.57% quarter-over-quarter from 12230.01% in Q2 2021.
Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 14257.07% for Q3 2021.
- In Q3 2021, EBITDA Margin fell 1149635.0% year-over-year to 14257.07%; the TTM figure through Jun 2022 stood at 45961.32% (down 4363525.0% YoY), while the FY2021 annual figure was 6350.09%, down 389388.0% from the prior year.
- EBITDA Margin for Q3 2021 stood at 14257.07%, down from 12230.01% in the prior quarter.
- The five-year high for EBITDA Margin was 95.17% in Q4 2019, with the low at 14257.07% in Q3 2021.
- The 5-year median for EBITDA Margin is 1386.11% (2018), against an average of 3257.6%.
- The sharpest annual moves came in 2019 and 2020: EBITDA Margin surged 145772 bps in 2019, then sank 1332495 bps in 2020.
- Corbus Pharmaceuticals Holdings' EBITDA Margin stood at 873.63% in 2017, then dropped by 4 bps to 912.72% in 2018, then soared by 110 bps to 95.17% in 2019, then plunged by 1371 bps to 1209.33% in 2020, then plunged by 1079 bps to 14257.07% in 2021.
- Business Quant data shows CRBP's EBITDA Margin at 14257.07% in Q3 2021, 12230.01% in Q2 2021, and 2379.38% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -14,257.07% |
| Jun 30, 2021 | -12,230.01% |
| Mar 31, 2021 | -2,379.38% |
| Dec 31, 2020 | -1,209.33% |
| Sep 30, 2020 | -2,760.72% |
| Jun 30, 2020 | -13,319.09% |
| Mar 31, 2020 | -1,696.04% |
| Dec 31, 2019 | 95.17% |
| Sep 30, 2019 | -969.07% |
| Jun 30, 2019 | 5.86% |
| Mar 31, 2019 | -1,406.53% |
| Dec 31, 2018 | -912.72% |
| Sep 30, 2018 | -1,365.69% |
| Jun 30, 2018 | -1,451.86% |
| Mar 31, 2018 | -1,248.36% |
| Sep 30, 2017 | -873.63% |
| Jun 30, 2017 | -2,082.20% |
| Mar 31, 2017 | -576.07% |
| Sep 30, 2016 | -718.30% |
| Jun 30, 2016 | -1,056.90% |